side-area-img-1
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis Theme

1-677-124-44227

[email protected]

184 MAIN COLLINS STREET WEST VICTORIA 8007

FOLLOW US ON INSTAGRAM
Etiam ultricies nisi vel augue. Curabitur ullamcorper ultricies

The No.1 Research Site For Therapeutic Peptides

Mobile Logo
Top

Tesamorelin 5mg

INTRODUCING

Tesamorelin 5mg

Tesamorelin, also known as Egrifta, is a synthetic analogue of growth hormone-releasing hormone (GHRH). It is a 44-amino acid peptide that stimulates the production and release of growth hormone (GH) from the pituitary gland. Tesamorelin has been primarily investigated for its potential to reduce excess abdominal fat in individuals with HIV-associated lipodystrophy, a condition characterized by abnormal fat distribution and metabolism.

Previous and ongoing research on tesamorelin has focused on several key areas:

  1. HIV-associated lipodystrophy: Tesamorelin has been extensively studied for its ability to reduce visceral adipose tissue (VAT) in HIV-infected patients with lipodystrophy, a condition that can lead to increased risk of cardiovascular diseases and metabolic complications.
  2. Metabolic effects: Tesamorelin’s effect on metabolism has also been investigated, with some studies indicating improvements in insulin sensitivity, glucose metabolism, and lipid profiles in patients with HIV-associated lipodystrophy.
  3. Potential applications in obesity: While the primary focus has been on HIV-associated lipodystrophy, tesamorelin’s ability to reduce VAT may have potential therapeutic applications in obesity and obesity-related complications.

Current research on tesamorelin is focused on further understanding its mechanisms of action, optimizing its therapeutic applications, and investigating its safety and efficacy in various populations and medical conditions. Some recent research papers related to tesamorelin include:

  1. Falutz, J., et al. (2018). “Tesamorelin for HIV-Associated Lipodystrophy: Effects on Liver Fat.” AIDS Research and Human Retroviruses, 34(11), 931-938. [This study investigates the effects of tesamorelin on liver fat in patients with HIV-associated lipodystrophy.]
  2. Stanley, T. L., et al. (2014). “Effects of tesamorelin on inflammatory markers in HIV-infected patients with excess abdominal fat: relationship with visceral adipose reduction.” AIDS, 28(9), 1269-1275. [This study explores the effects of tesamorelin on inflammatory markers and their relationship with VAT reduction in HIV-infected patients.]
  3. Falutz, J., et al. (2010). “Efficacy and safety of tesamorelin, a growth hormone-releasing factor analogue, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.” Journal of Acquired Immune Deficiency Syndromes, 55(3), 299-305. [This pooled analysis of two phase 3 trials evaluates the efficacy and safety of tesamorelin in reducing abdominal fat in HIV-infected patients with lipodystrophy.]

Peptides are the future of medicine. They are potent, tissue specific and effective at treating a variety of conditions with little to no side effects.

Dean Henry
Function Medicine Coach and Health Optimiser

Peptides are the next frontier in biohacking and performance enhancement. They can boost muscle growth, accelerate fat loss, improve sleep, increase energy and focus, and promote overall health and longevity.

Ben Greenfield
Biohacker and Health Expert

Peptides are tiny chains of amino acids that have powerful effects on the brain and body. They can improve memory, focus, and mood, and have anti-anxiety and anti-depressant effects.

Dr. Andrew Huberman, PhD
Professor of Neurobiology at Stanford University